Alpha Teknova, Inc. (TKNO)

NASDAQ: TKNO · IEX Real-Time Price · USD
2.460
-0.040 (-1.60%)
At close: Mar 27, 2024, 4:00 PM
2.500
+0.040 (1.63%)
After-hours: Mar 27, 2024, 4:00 PM EDT

Company Description

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics.

The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions.

The company was founded in 1996 and is headquartered in Hollister, California.

Alpha Teknova, Inc.
Alpha Teknova logo
Country United States
Founded 1996
IPO Date Jun 25, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 285
CEO Stephen Gunstream

Contact Details

Address:
2451 Bert Drive
Hollister, California 95023
United States
Phone (831) 637-1100
Website teknova.com

Stock Details

Ticker Symbol TKNO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001850902
CUSIP Number 02080L102
ISIN Number US02080L1026
Employer ID 94-3368109
SIC Code 2835

Key Executives

Name Position
Stephen Gunstream President, Chief Executive Officer and Director
Matthew C. Lowell Chief Financial Officer
Damon A. Terrill General Counsel, Chief Compliance Officer and Secretary
Jennifer Henry Senior Vice President of Marketing

Latest SEC Filings

Date Type Title
Mar 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2024 10-K Annual Report
Mar 11, 2024 8-K Current Report
Feb 22, 2024 DEF 14C Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 16, 2024 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Nov 9, 2023 424B3 Prospectus
Nov 7, 2023 EFFECT Notice of Effectiveness